Accelerating A Schizophrenia Trial While Ensuring Quality

When a neuroscience biotech needed to enroll its first participant in a Phase IIa schizophrenia trial within 60 days of contract award, speed and quality had to coexist from day one. This case study details how a trial team exceeded that milestone by activating and enrolling the first participant in just six weeks, and then adapted when the stakes got even higher.

Through coordinated action, including expanded clinic space, intensified recruitment, and real-time data monitoring, every subject was completed on time, and results were delivered ahead of the revised deadline. If your trial is facing shifting timelines or unexpected protocol demands, this case study offers a practical look at how proactive planning and cross-team alignment can keep your program on track without sacrificing data quality.